| Today’s Big NewsDec 18, 2023 |
| By Max Bayer Biotech investors are licking their wounds after a year that's likely to have the lowest level of new fundraising in four years. Will 2024 finally be the rebound year? |
|
|
|
By Kevin Dunleavy The FDA has signed off on Astellas and Pfizer’s Padcev in combination with Merck’s Keytruda as a first-line treatment for bladder cancer. The full endorsement, which follows an accelerated nod eight months ago, puts the combo on course to replace chemotherapy as the standard of care in locally advanced or metastatic urothelial cancer. |
By Andrea Park With only a week left in President Biden’s review of a proposed import ban on Apple Watches containing a pulse oximetry feature, Apple is preemptively complying with the sales stoppage. |
By Angus Liu GSK has more positive data to report in endometrial cancer as the company's PD-1/PARP combination turned in a trial win. The combination could represent a threat to a rival therapy at AstraZeneca. |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now.
|
|
By Gabrielle Masson Against a backdrop of a tough funding environment, nearly half of biotechs are using partnerships with Big Pharmas as a financing method, according to a survey commissioned by CRO Icon. |
By Conor Hale The DNA sequencing giant announced it will aim to finalize the details of the divestiture within the first six months of the new year—whether it be through a sale to an interested suitor or by having Grail take itself public. |
By Zoey Becker The company opted to cut the phase 3 Relativity-123 study after an analysis found that the trial was unlikely to achieve its primary endpoints in microsatellite-stable patients with metastatic colorectal cancer. |
By Gabrielle Masson The Novo Nordisk Foundation is dedicating up to $260 million to create new or improved vaccines for serious respiratory diseases, such as tuberculosis (TB) and the flu. |
By Andrea Park Less than two years after Zimmer Biomet spun out its spine and dental businesses into a separate, standalone company, the resulting entity, ZimVie, is already undergoing another transformation. |
By Zoey Becker Once again, shareholders with the Interfaith Center on Corporate Responsibility are raising access concerns in proposals to several top drugmakers. |
By Nick Paul Taylor It's decision time for Point Biopharma investors. Having dragged out the Eli Lilly buyout, investors now have phase 3 radiopharmaceutical data to compare to Novartis’ results—and days to choose whether to cash out or reject the existing offer. |
By Andrea Park Even after decades of experience developing eye-related devices under its belt, Carl Zeiss Meditec is still looking to expand its ophthalmic portfolio. |
Fierce podcastsDon’t miss an episode |
| | The Fierce 50 honorees range from tech innovators to researchers developing novel therapies to providers on the frontlines of changing care. This week on "The Top Line," senior editor Paige Minemyer sat down with staff writers Dave Muoio and Anastassia Gliadkovskaya as well as senior editor Heather Landi to discuss a few of the honorees in more detail. |
|
|---|
|
|
|
Learn how applying a Quality By Design framework in clinical trials saves time, money, and resources by reducing protocol amendments based on past learnings and the design, carrying forward key learnings to benefit future trials, and delivering consistent and efficient delivery of reliable data. Download now.
|
|
| WhitepaperDownload this whitepaper to discover the 3 pillars of successful PK testing and conquer bioanalytical challenges. Sponsored by: Sannova Analytical |
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. S3 Connected Health |
| WhitepaperqPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
| WhitepaperStreamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
| Whitepaper High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
| Executive SummaryBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| WhitepaperLearn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
| Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
| Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| |
|
